Wyeth Opens World's Largest Integrated Biotech Production Facility
Ireland Plant centerpiece of Wyeth's growing investment in biotech processes and products
Wyeth formally opened its Grange Castle biotech production facility in South County Dublin, Ireland. The new 1.2 million square foot campus is one of the largest integrated biotech manufacturing facilities in the world and is expected to produce some of the Company's most innovative products.
Wyeth invested nearly $2 billion in the Grange Castle facility, where site development work began in October 2002. The campus at Grange Castle, which employs more than 1,000 people, will comprise three separate facilities - a drug development unit, a drug substance site, and a drug product facility. These facilities will go into production on a phased basis over the next four years. With the addition of Grange Castle to Wyeth's existing manufacturing sites in Ireland, Wyeth has now become the country's largest pharmaceutical employer.
Among the biotech products that will be produced at Grange Castle is Enbrel, for which Wyeth owns the rights outside the U. S. Enbrel is approved in many markets around the world and can be used to treat rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriasis and psoriatic arthritis. Prevenar is also scheduled to be produced at Grange Castle, as is the Company's newly FDA approved intravenous (IV) antibiotic Tygacil(TM) (tygacycline IV), used for the treatment of serious skin and intra-abdominal hospital acquired infections.
Other news from the department manufacturing
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
